$20.08-0.22 (-1.08%)
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally.
OrthoPediatrics Corp. in the Healthcare sector is trading at $20.08 with a market capitalization of $477M. Wall Street consensus targets $24.67 (9 analysts), implying a +22.8% move over the next 12 months. The stock is currently 15% below its 52-week high of $23.70, remaining 14.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $59.36M↓ | $61.60M↑ | $61.25M↑ | $61.08M↑ | $52.41M |
| Gross Profit | $43.39M↓ | $45.11M↓ | $45.27M↑ | $44.02M↑ | $38.26M |
| Operating Income | -$8.34M↓ | -$5.51M↓ | -$4.87M↑ | -$7.69M↑ | -$10.94M |
| Net Income | -$10.69M↓ | -$10.10M↑ | -$11.77M↓ | -$7.11M↑ | -$10.66M |
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. ...
OrthoPediatrics is back in focus after recent Street research prompted both upward and downward revisions to the stock’s price target, including a US$1 lift in the consensus level alongside US$3 cuts from more cautious analysts. The mixed reaction captures how different firms are interpreting the same set of assumptions and news flow, with some emphasizing long term growth potential and others stressing execution and margin risk. As you read on, you will see how these shifting price targets...
OrthoPediatrics enters this update cycle with no change to its existing price target, giving you a steady reference point as the story develops. Even without a fresh valuation reset or new analyst commentary to dissect, the lack of movement can still tell you something about how expectations are holding. Read on to see how to track this kind of quiet update and follow the evolving narrative around the stock. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other...
The blended fair value estimate for OrthoPediatrics has shifted from US$24.00 to about US$24.67 per share, reflecting a modest adjustment to the stock’s perceived potential. This move sits alongside a split in Street views, where some analysts have raised targets into the low US$20s while others have trimmed their numbers, leaving the overall narrative more finely balanced. As you read on, you will see how this evolving analyst debate can help you frame your own view on the stock. Analyst...
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a sharp macro-driven sector rotation following geopolitical tensions, which triggered inflation fears and rising interest rate […]
OrthoPediatrics Corp (KIDS) reports a 13% revenue increase and raises 2026 guidance, while navigating weather impacts and cautious product launch timelines.